UPC Analytics
ENDE
Overview · Filed:

ACT_56003/2024

FLUID DELIVERY DEVICE WITH TRANSCUTANEOUS ACCESS TOOL, INSERTION MECHANISM AND BLOOD GLUCOSE MONITORING FOR USE THEREWITH

RevocationMain Revocation ActionMilan CDRevocation Action
Parties

Claimants

  • Insulet Corporation
Reps: Frank Peterreins (Peterreins Schley Patent- und Rechtsanwälte PartGmbH)

Respondents

  • EOFLOW Co., Ltd.
Reps: Christopher Pierce (Hoyng Rokh Monegier)
Judges
  • Andrea PostiglionePresiding judge and judge-rapporteur
  • Anna-Lena KleinLegally qualified judge
  • Uwe SchwengelbeckTechnically qualified judge
Patents
  • EP4201327
CPC codes: A61M5/1723, A61M5/1452, A61M5/158, A61B5/14865, A61M5/14244, F04B9/02, A61B5/14532, A61M2230/201, A61M2005/14506, A61M5/14248, B65D83/761, A61M5/3291

Technology area: Medical Devices · CGM

Sector: Packaging & Conveying

Outcome
InfringedMaintained as granted
Filed:
First decided: Apr 11, 2025
Last decision: Jul 22, 2025
Language:

Milan Central Division decision by default on EOFLOW's revocation action (dismissed) and on Insulet's counterclaim for infringement of a patent for wearable insulin delivery devices (patch pump). EOFLOW failed to defend and the Court verified sufficiency of evidence before issuing the default decision. The Court upheld Insulet's infringement claim and granted an injunction ordering EOFLOW to cease infringing acts, provide information/accounts, recall infringing products, and pay compensation for damages since 19 June 2024. The revocation action by EOFLOW was dismissed for lack of prosecution. Costs borne by EOFLOW. Patent terms interpreted according to principal functional meaning. The cost cap applies per instance regardless of number of parties or patents (Administrative Committee decision of 24 March 2023).

Claims
At issueall
Maintainedall
Infringedall
Notes: Milan Central Division (same decision as CC_65201/2024 and ORD_22456/2025) found EOFLOW infringed EP 4 201 327 by default; revocation action dismissed; no specific claim numbers in excerpt.